Intellia Therapeutics Shares Plummet After Clinical Trial Halt and Analyst Downgrade
27.11.2025 - 10:14:05Intellia Therapeutics US45826J1051
A dramatic reassessment is underway for Intellia Therapeutics, sending shockwaves through the biotech investment community. Market research firm Morningstar has executed a severe cut to its fair value estimate for the company, slashing it by more than half. This move signals a fundamental shift in how Wall Street is evaluating the risk profile of the gene-editing firm, raising questions about restored investor confidence.
From a financial standpoint, Intellia retains a solid position. The company reported a cash position of approximately $670 million as of the third quarter, which is projected to fund operations through mid-2027. This financial buffer provides management with crucial breathing room to address regulatory challenges without the immediate pressure Read more...
